1. From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
JCHF. 2016;4(5): doi: /j.jchf
Figure Legend:
Patients enter the model and are placed on either sacubitril-valsartan or enalapril. Patients who experience clinical events are transitioned through the health states of New York Heart Association (NYHA) functional class I, II, III, IV, or death once every 3 months. *Death was subgrouped by all-cause or cardiovascular specific causes for model validation. BID = twice a day; HF = heart failure; HFrEF = heart failure with reduced ejection fraction.
Date of download: 9/19/2016
Copyright © The American College of Cardiology. All rights reserved.

2. From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
JCHF. 2016;4(5): doi: /j.jchf
Figure Legend:
Changes in the incremental cost-effectiveness ratio (ICER) over the first 20 years after initiation of either sacubitril-valsartan or enalapril. The earliest measured ICER is at 3 years, which is the duration of follow-up observed in PARADIGM-HF. ICER = incremental cost-effectiveness ratio; PARADIGM-HF = Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure; QALY = quality-adjusted life-year.
Date of download: 9/19/2016
Copyright © The American College of Cardiology. All rights reserved.

3. From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
JCHF. 2016;4(5): doi: /j.jchf
Figure Legend:
The change in the ICER of sacubitril-valsartan vs enalapril associated with varying model inputs across a plausible range of values is shown. Only variables that affected the outcome by >$1,000 are displayed. CV = cardiovascular; other abbreviations as in Figures 1 and 2.
Date of download: 9/19/2016
Copyright © The American College of Cardiology. All rights reserved.

4. From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
JCHF. 2016;4(5): doi: /j.jchf
Figure Legend:
Probabilistic sensitivity analysis results of 10,000 model simulations. Results reflect the effect of uncertainty in the model on differences in costs and quality-adjusted life-years (QALYs) for patients taking sacubitril-valsartan relative to those taking enalapril.
Date of download: 9/19/2016
Copyright © The American College of Cardiology. All rights reserved.

5. From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
JCHF. 2016;4(5): doi: /j.jchf
Figure Legend:
Kaplan-Meier estimates of survival from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (10) along with observed survival in the simulation model.
Date of download: 9/19/2016
Copyright © The American College of Cardiology. All rights reserved.